SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lynestrenol Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Lynestrenol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : Organon & Co.
              Shotton Lane
              NE23 3JU Cramlington NU - Great Britain
   Telephone : 44 1 670 59 30 00
   E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number
   215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Germ cell mutagenicity, Category 1B  H340: May cause genetic defects.
   Carcinogenicity, Category 2  H351: Suspected of causing cancer.
   Reproductive toxicity, Category 1A  H360Fd: May damage fertility. Suspected of damaging the unborn child.
   Specific target organ toxicity - repeated exposure, Category 2  H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :

   Signal word : Danger
   Hazard statements : H340  May cause genetic defects.
                      H351  Suspected of causing cancer.
                      H360Fd  May damage fertility. Suspected of damaging the unborn child.
                      H373  May cause damage to organs through prolonged or repeated exposure.
Precautionary statements:

**Prevention:**
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**
P405 Store locked up.

**Hazardous components which must be listed on the label:**
Lynestrenol

**Additional Labelling**
EUH208 Contains Tocopherol. May produce an allergic reaction.

**2.3 Other hazards**
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients**

**3.2 Mixtures**

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lynestrenol</td>
<td></td>
<td>52-76-6</td>
<td>200-151-4</td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302 Muta. 1B; H340 Carc. 2; H351 Repr. 1A; H360Fd STOT RE 1; H372 (Blood, Mammary gland, Uterus (including cervix), Ovary)</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tocopherol</td>
<td></td>
<td>10191-41-0</td>
<td>233-466-0</td>
<td></td>
<td></td>
<td>Skin Sens. 1B; H317</td>
<td>&gt;= 0.1 - &lt; 1</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause genetic defects. Suspected of causing cancer. May damage fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May produce an allergic reaction.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and dis-
posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
SAFETY DATA SHEET
according to Regulation (EO) No. 1907/2006

Lynestrenol Formulation

Version 3.5  Revision Date: 09.04.2021  SDS Number: 462436-00012  Date of last issue: 10.10.2020

Date of first issue: 15.01.2016

Gases

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA (inhalable dust)</td>
<td>10 mg/m³</td>
<td>GB EH40</td>
</tr>
</tbody>
</table>

Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols. The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits. Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed ‘inhalable’ and ‘respirable’. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4. Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with. Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.

<table>
<thead>
<tr>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWA (Respirable dust)</td>
<td>4 mg/m³</td>
<td>GB EH40</td>
</tr>
</tbody>
</table>

Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols. The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits. Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after
entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4. Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with. Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>56 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>229 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>33 mg/m3</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lynestrenol Formulation

Version 3.5
Revision Date: 09.04.2021
SDS Number: 462436-00012
Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

<table>
<thead>
<tr>
<th>Tocopherol</th>
<th>Workers</th>
<th>Inhalation</th>
<th>44 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Workers</td>
<td>Skin contact</td>
<td></td>
<td>125 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td></td>
<td>10.8 mg/m³</td>
</tr>
<tr>
<td>Consumers</td>
<td>Skin contact</td>
<td></td>
<td>62.5 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td></td>
<td>6.25 mg/kg bw/day</td>
</tr>
</tbody>
</table>

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>Fresh water</td>
<td>0.885 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.0885 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>8.85 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>3.3 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.33 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.141 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

**8.2 Exposure controls**

**Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

**Personal protective equipment**

**Eye protection**

Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

**Material**

Chemical-resistant gloves

**Remarks**

Consider double gloving.

**Skin and body protection**

Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**

If adequate local exhaust ventilation is not available or expo-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lynestrenol Formulation

Version 3.5  Revision Date: 09.04.2021  SDS Number: 462436-00012  Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

sure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to BS EN 14387
Filter type: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- Appearance: powder
- Colour: No data available
- Odour: No data available
- Odour Threshold: No data available
- pH: No data available
- Melting point/freezing point: No data available
- Initial boiling point and boiling range: No data available
- Flash point: Not applicable
- Evaporation rate: Not applicable
- Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
- Flammability (liquids): No data available
- Upper explosion limit / Upper flammability limit: No data available
- Lower explosion limit / Lower flammability limit: No data available
- Vapour pressure: Not applicable
- Relative vapour density: Not applicable
- Relative density: No data available
- Density: No data available
- Solubility(ies)
  - Water solubility: No data available
  - Partition coefficient: n-octanol/water: Not applicable
  - Auto-ignition temperature: No data available
- Decomposition temperature: No data available
- Viscosity
  - Viscosity, kinematic: Not applicable
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
Particle size: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure: Inhalation, Skin contact, Ingestion, Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
Lynestrenol:
Acute oral toxicity: LD50: > 1,000 - 8,000 mg/kg
Acute toxicity (other routes of administration):
LD50 (Mouse): 110 mg/kg
Application Route: Intraperitoneal

**Tocopherol:**

Acute oral toxicity:
LD50 (Rat): > 4,000 mg/kg

Acute dermal toxicity:
LD50 (Rat): > 3,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Tocopherol:**
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Tocopherol:**
Species: Rabbit
Method: OECD Test Guideline 405
Result: No eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**Tocopherol:**
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Method: OECD Test Guideline 429
Result: positive
Assessment: Probability or evidence of low to moderate skin sensitisation rate in humans

**Germ cell mutagenicity**
May cause genetic defects.
Components:

Lynestrenol:

Genotoxicity in vitro:
- Test Type: Chromosome aberration test in vitro
  Result: positive
- Test Type: sister chromatid exchange assay
  Result: positive

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  Species: Mouse
  Application Route: Intraperitoneal injection
  Result: positive
- Test Type: sister chromatid exchange assay
  Species: Mouse
  Application Route: Intraperitoneal injection
  Result: positive
- Test Type: dominant lethal test
  Species: Mouse
  Application Route: Intraperitoneal
  Result: positive

Germ cell mutagenicity—Assessment:
- Positive result(s) from in vivo somatic cell mutagenicity tests in mammals. Evidence that the substance has potential to cause mutations to germ cells

Tocopherol:

Genotoxicity in vitro:
- Test Type: Chromosome aberration test in vitro
  Method: OECD Test Guideline 473
  Result: negative
  Remarks: Based on data from similar materials

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Ingestion
  Result: negative
  Remarks: Based on data from similar materials

Carcinogenicity
Suspected of causing cancer.

Components:

Lynestrenol:

Species: Mouse
Application Route: Oral
Exposure time: 80 weeks
Result: positive
Tumor Type: breast tumors, Liver
Remarks: Benign and malignant tumor(s)
Species: Rat
Application Route: Oral
Exposure time: 80 weeks
Result: positive
Tumor Type: breast tumors

Carcinogenicity - Assessment: Limited evidence of carcinogenicity in animal studies

Tocopherol:
Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
May damage fertility. Suspected of damaging the unborn child.

Components:

Lynestrenol:
Effects on fertility:
  Test Type: Fertility/early embryonic development
  Species: Rat, males
  Application Route: Oral
  Fertility: LOAEL: 20 mg/kg body weight
  Remarks: Impaired spermatogenesis
  Test Type: Fertility/early embryonic development
  Species: Rat, females
  Application Route: Oral
  Fertility: LOAEL: 375 µg/kg
  Result: Maternal toxicity observed., Effects on fertility
  Test Type: Fertility/early embryonic development
  Species: Rabbit
  Application Route: Oral
  Fertility: LOAEL: 1,300 µg/kg
  Result: Effects on fertility, Postimplantation loss.

Effects on foetal development:
  Test Type: Embryo-foetal development
  Species: Rat
  Application Route: Oral
  Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
  Result: Effects on foetal development
  Test Type: Embryo-foetal development
  Species: Rabbit
  Application Route: Oral
  Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
  Result: Effects on foetal development, Postimplantation loss.
Reproductive toxicity - Assessment
: Some evidence of adverse effects on development, based on animal experiments., Positive evidence of adverse effects on sexual function and fertility from human epidemiological studies.

Tocopherol:
Effects on foetal development
: Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Lynestrenol:
Target Organs
Assessment
: Blood, Mammary gland, Uterus (including cervix), Ovary
: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Tocopherol:
Species
NOAEL
Application Route
Exposure time
Remarks
: Rat
: 500 mg/kg
: Ingestion
: 90 Days
: Based on data from similar materials

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Lynestrenol:
Ingestion
: Target Organs: Uterus (including cervix)
Target Organs: breasts
Target Organs: ovaries
Target Organs: Blood
Symptoms: Headache, Nausea, Abdominal pain, Rash, Dizziness, Tremors, Sweating, Vomiting, migraine, acne, breast tenderness, gynecomastia, menstrual irregularities, ovarian cysts
Remarks: Used to prevent pregnancy
SECTION 12: Ecological information

12.1 Toxicity

Components:

Tocopherol:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
   Exposure time: 96 h
   Method: OECD Test Guideline 203
   Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 23.53 mg/l
   Exposure time: 48 h
   Method: OECD Test Guideline 202
   Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: NOEC (Pseudokirchneriella subcapitata (green algae)): 25.8 mg/l
   Exposure time: 72 h
   Method: OECD Test Guideline 201
   Remarks: No toxicity at the limit of solubility

   EC50 (Pseudokirchneriella subcapitata (green algae)): > 25.8 mg/l
   Exposure time: 72 h
   Method: OECD Test Guideline 201
   Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms: EC50: > 937 mg/l
   Exposure time: 30 min
   Method: ISO 8192
   Remarks: Based on data from similar materials

Toxicity to fish (Chronic toxicity): NOEC: > 100 mg/l
   Exposure time: 28 d
   Species: Oncorhynchus mykiss (rainbow trout)
   Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:

Tocopherol:
Biodegradability: Result: Not readily biodegradable.
   Biodegradation: 20 %
   Exposure time: 28 d
   Method: OECD Test Guideline 301F

12.3 Bioaccumulative potential

No data available
12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

Product: Assesment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product: Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks : Not applicable for product as supplied.
SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable


Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H317 : May cause an allergic skin reaction.
H340 : May cause genetic defects.
H351 : Suspected of causing cancer.
H360Fd : May damage fertility. Suspected of damaging the unborn child.
H372 : Causes damage to organs through prolonged or repeated
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lynestrenol Formulation

Full text of other abbreviations

Acute Tox.: Acute toxicity
Carc.: Carcinogenicity
Muta.: Germ cell mutagenicity
Repr.: Reproductive toxicity
Skin Sens.: Skin sensitisation
STOT RE: Specific target organ toxicity - repeated exposure
GB EH40: UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA: Long-term exposure limit (8-hour TWA reference period)

Further information


Classification of the mixture:

<table>
<thead>
<tr>
<th>Muta.</th>
<th>Carc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1B</td>
<td>2</td>
</tr>
<tr>
<td>H340</td>
<td>H351</td>
</tr>
</tbody>
</table>

Classification procedure:

Calculation method
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lynestrenol Formulation

Version 3.5
Revision Date: 09.04.2021
SDS Number: 462436-00012
Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

Repr. 1A H360Fd Calculation method
STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN